Abstract:
The present invention concerns a method and a system for the prediction of short functional significant protein sequences. In particular, the invention is related to a method of predicting phosphorylation sites in protein sequences. The invention is based on a case-based, on-the-fly model generation for prediction. The invention is described by the example of predicting phosphorylation sites in unknown protein sequences but is applicable for the prediction of any functional significant protein sequence in a longer protein sequence to be analysed.

Description:
BACKGROUND OF THE INVENTION  
         [0001]    1. Field of the Invention  
           [0002]    The present invention concerns a method and a system for the prediction of short functional significant protein sequences. In particular, the invention is related to a method of predicting phosphorylation sites in protein sequences. The invention is based on a case-based, on-the-fly model generation for prediction.  
           [0003]    The invention is described by the example of predicting phosphorylation sites in unknown protein sequences but is applicable for the prediction of any functional significant protein sequence in a longer protein sequence to be analysed.  
           [0004]    2. Description of the Related Art  
           [0005]    Phosphorylation is one of the most important mechanisms in the regulation of cellular processes by the posttranslational modification of enzymes, receptors and other proteins. Phosphorylation is a chemical process in which a phosphate group is added to an organic molecule associated with respiration and photosynthesis in living cells. The prediction of unknown functional sites, especially of unknown phosphorylation sites, is difficult as functional sites, especially phosphorylation sites, are usually short in length (not longer than about ten amino acid residues). Due to the short length common sequence alignment tools, e.g. the BLAST algorithm as described in Altschul S. F. and Lipman D. J. (1990), Basic Local Alignment Search Tool, J. Mol. Biol. 215, 404-410, or FASTA as described in Pearson W. R. and Lipman D. J. (1988), Improved Tools for Biological Sequence Analysis, Proc. Natl. Acad. Sci 85, 2444-2448, yield no useful results because of a large number of irrelevant predictions.  
           [0006]    For the prediction of functional patterns in protein sequences, the motif approach emerged in methods like PROSITE as described in Hofmann K., Bucher P., Falquet L., and Bairoch A. (1999),  The PROSITE database, its status in  1999, Nucleic Acids Res. 27, 215-219, BLOCKS as described in Henikoff S., Henikoff J. G. and Pietrokovski S. (1999), Blocks+: A non-redundant database of protein alignment blocks derived from multiple compilations, Bioinformatics 15, 471-479, or PRINTS as described in Attwood T. K., Flower D. R., Lewis A. P., Mabey J. E., Morgan S. R., Scordis P., Selley J., and Wright, W. (1999),  PRINTS prepares for the new millennium , Nucleic Acids Res. 27, 220-225, which use local sequence patterns (or motifs) to help identifying function or activity of proteins. Local sequence information means several contiguous amino acid residues. PROSITE is representative of the general motif approach.  
           [0007]    PROSITE is a method to determine the function of not characterized proteins translated from genomic or cDNA sequences. It comprises a database of biologically significant sites and patterns formulated so that it can be rapidly and reliably identified by appropriate computational tools to which known protein family (if any) the new detected sequence is assigned. A pattern describes a group of amino acids that constitutes an usually short but characteristic motif within a protein sequence. The pattern syntax allows the expression of ambiguities, for example if two different amino acids are allowed at a given position. For example, the pattern  
           [0008]    [AC]-x-V-x(4)-{ED} 
           [0009]    is interpreted as [Ala or Cys]-any-Val-any-any-any-any-{any but Glu or Asp}. In addition to patterns a variant of PROSITE uses profiles as described more detailed in the PROSITE User Manual.  
           [0010]    A profile, i.e a weight matrix, is a table of position-specific amino acid weights and gap costs. These numbers are used to calculate a similarity score between the profile and a sequence to be analysed. A similarity score higher than or equal to a given cut-off value constitutes a motif occurrence. Profiles can be constructed by a large variety of different techniques. The classical method is disclosed in Gribskov M. and Devereux J. (1992),  Sequence analysis primer , Freeman and Company, and requires a multiple sequence alignment as input. It uses a symbol comparison table to convert distributions of the number of residue occurrences into weight values. Profiles are supposed to be more sensitive than patterns because they individually assign weights to single residues, while pattern approaches can only be applied to detect matching or non-matching with a single residue.  
           [0011]    Instead of profiles or weight matrices also hidden Markov models (HMMs) or artificial neural networks (NN) can be used. PFAM (Protein Families Database of Alignments) is a collection of protein motifs and families, see also Bateman A., Birney E., Durbin R., Eddy S. R., Howe K. L., Sonnhammer E. L. (2000),  The Pfam Protein Families Database , Nucleic Acids Research 28, 263-266. It is possible to convert a PFAM HMM into a profile, both resulting in nearly the same similarity scores when applied to the same sequence. Although a few minor technical differences subsist for practical applications, PFAM HMMs and PROSITE profiles are substantially mutually convertible. However, this cannot be extended to other applications involving HMMs. Many biological motifs are described both by a PROSITE profile and a PFAM HMM. The results generated by these two models and methods, respectively, are usually different. This is probably caused by the different biological considerations which are applied for the multiple alignment on which both methods substantially rely. In a similar way weight matrices (short ‘matrices’) can be applied to certain architectures of neural networks where each weight of a synapse of the neural network corresponds to a specific value of a weight matrix. Introducing an additional layer to a neural network then corresponds to a matrix where each layer represents a combination of several amino acids.  
           [0012]    An implementation of neural networks for the prediction of phosphorylation sites is realised by NETPHOS that is described in Blom N., Gammeltoft S. and Brunak S. (1999), Sequence and Structure-based Prediction of Eukaryotic Protein Phosphorylation Sites, J. Mol. Biol. 294, 1351-1361. While approaches like PROSITE use a whole set of patterns or matrices NETPHOS establishes three separate neural networks, each for one of three phosphorylation acceptor residues, namely tyrosine (Y), serine (S) and threonine (T). In the document Blom N., Gammeltoft S. and Brunak S. (1999), Sequence and Structure-based Prediction of Eukaryotic Protein Phosphorylation Sites, J. Mol. Biol. 294, 1351-1361, the construction of individual neural networks for individual groups of known phosphorylation sites is mentioned.  
           [0013]    Two of the above described approaches are commonly applied NETPHOS and PROSITE patterns.  
           [0014]    The NETPHOS approach advantageously provides automatic learning. The neural network incorporates all known functional protein sequences in one model, e.g. the phosphorylation sites of one acceptor residue (T, S or Y). There is no need of manually maintaining and using several sets of models.  
           [0015]    On the other hand, the pattern/matrix approach leads to more accurate and individual models for the prediction of phosphorylation sites.  
           [0016]    Both approaches, the NETPHOS implementation and the pattern/matrix approach, have the drawback of relying on predefined models including known phosphorylation sites which had been compiled previously by more or less unknown conditions or circumstances. The models are manually predefined which may result in predictions with different accuracy. Therefore, a general uncertainty and unavoidable bias and error is to expect in the prediction models. The bias and error necessarily lead to a higher uncertainty in prediction which will automatically result in a reduced sensitivity and specificity of the predictions.  
           [0017]    The problem underlying the present invention is therefore to provide a method for the detection of unknown functional protein sequences within a given protein sequence which overcomes the drawbacks of the methods of the prior art.  
         SUMMARY OF THE INVENTION  
         [0018]    In a first aspect the problem underlying the present invention is solved by a method for the detection of an unknown functional protein sequence within a given protein sequence having a number of amino acids comprising the following steps:  
           [0019]    a) providing said given protein sequence having a number of amino acids wherein functional sites shall be predicted;  
           [0020]    b) providing a number of known functional protein sequences having a number of contiguous amino acids wherein said known functional protein sequences include proven functional sites;  
           [0021]    c) for each of said known functional protein sequences, evaluating a resemblance score at one ore more alignment positions between the known functional protein sequences and a portion of said given protein sequence which is to be analysed;  
           [0022]    d) if said resemblance scores exceeds a minimum resemblance threshold, selecting the known functional protein sequence(s) and their alignment position(s);  
           [0023]    e) assigning each of the selected known functional protein sequence to a segment of said given protein sequence according to their alignment position(s) wherein said segment is defined by said one or more alignment positions;  
           [0024]    f) for each of the segments, creating a matrix containing the number of occurrences of each amino acid at a specific position of said given protein sequence aligned with the respective segment,  
           [0025]    g) for each of the matrices, evaluating an overall similarity between the known functional protein sequences assigned to the respective segment and the portion of the given protein sequence related to said evaluated segment, and evaluating a conservation value rating the occurrence of conserved amino acids within the evaluated segment.  
           [0026]    In an embodiment of the inventive method the alignment positions of one of said known functional protein sequences are selected if the resemblance score of one of said known functional protein sequence has a maximum resemblance score relating to said maximum resemblance scores at all alignment positions.  
           [0027]    In a preferred embodiment of the inventive method step c) of evaluating said resemblance scores at one ore more alignment positions includes the evaluation of said resemblance scores at all alignment positions.  
           [0028]    In another embodiment of the inventive method it is envisaged that according to step e) said selected known functional protein sequences are assigned into the same segment if their selected alignment positions are equal.  
           [0029]    In a further embodiment of the inventive method it is envisaged that according to step e) said selected known functional protein sequences are assigned into the same segment if their selected alignment positions are within a predetermined segmentation range.  
           [0030]    In still a further embodiment of the inventive method it is envisaged that successive known functional protein sequences are assigned to the same segment if the distance of said successive known functional protein sequences is less than half of the matrix length.  
           [0031]    In a preferred embodiment of the inventive method the evaluation of the overall similarity of step g) is performed only if the number of known functional protein sequences assigned to one segment exceeds a predetermined threshold number of known functional protein sequences, otherwise the segment is discarded.  
           [0032]    In a more preferred embodiment of the inventive method it is envisaged that the predetermined threshold number of known functional protein sequences is at least 3.  
           [0033]    In a further embodiment of the inventive method it is envisaged that the evaluation of the overall similarity of step g) further includes the step of  
           [0034]    for each of said matrices, evaluating said overall similarity using the formula  
       overallsim   :=       overall_similarity                   (     ups   ,   m     )       :=       ∏     l   =   1     s                       (       p   lAl       p   lO       )     .                               
 
           [0035]    wherein ups is the specific portion of the given protein sequence aligned with the respective segment,  
           [0036]    wherein m is the matrix,  
           [0037]    wherein s is the length of the specific portion of the given protein sequence,  
           [0038]    wherein p10 is the maximum number of occurrences of a specific amino acid, and  
           [0039]    wherein P1A1 is the number of occurrences of the amino acid at the respective position of the specific portion of the given protein sequence.  
           [0040]    In another embodiment of the inventive method the evaluating of said conservation value conservation rating the occurrence of conserved amino acids within the evaluated segment is performed using the formula  
       conservation   :=       1   /   s     *       ∑   l                             (         log   base          (   20   )       +       ∑   lA                    p     1      A       *       log   base          (     p     1      A       )             )                               
 
           [0041]    wherein s is the total number of possible amino acids for each of the positions,  
           [0042]    wherein base is the basis of the logarithm, preferably 2 or 10,  
           [0043]    wherein p lA  denotes the evaluated probability of the occurrences of the specific amino acid in the respective column l of said matrix.  
           [0044]    In a further embodiment of the inventive method step e) of assigning each of the selected known functional protein sequence to a segment of said given protein sequence according to their alignment position(s) is performed if said overall similarity of the segment including the assigned known functional protein sequence exceeds the overall similarity of the segment without said known functional protein sequence, and/or if the conservation value of said segment including the assigned known functional protein sequence exceeds the conservation value of said segment without said assigned known functional protein sequence.  
           [0045]    In another aspect the problem underlying the present invention is solved by a method for the verification of an unknown functional protein sequence comprising the steps of the inventive method for the detection of an unknown functional protein sequence within a given protein sequence having a number of amino acids, resulting in an annotated unknown functional protein sequence whereby the annotated unknown functional protein sequence is a functional protein sequence having a minimum overall similarity and/or a minimum conservation value, further comprising the step of experimentally verifying the annotated unknown functional protein sequence.  
           [0046]    In still another aspect the problem underlying the present invention is solved by the use of any of the inventive methods for predicting phosphorylation sites in a given protein sequence, wherein the known functional protein sequences contain proven phosphorylation sites.  
           [0047]    In a further aspect the problem underlying the present invention is solved by an apparatus for the detection of an unknown functional protein sequence within a given protein sequence, wherein said given protein sequence includes a number of amino acids wherein functional sites shall be predicted, wherein a number of known functional protein sequences having proven functional sites are provided which include a number of contiguous amino acids, comprising:  
           [0048]    means for evaluating a resemblance score between the known functional protein sequences and a portion to be analysed of said given protein sequence at one ore more alignment positions for each of said known functional protein sequences;  
           [0049]    selecting means to select the known functional protein sequence and their alignment positions, if said resemblance scores exceed a minimum resemblance threshold,  
           [0050]    assigning means to assign each of the selected known functional protein sequences to a segment according to their alignment position wherein said segment is defined by said one or more alignment positions,  
           [0051]    overall similarity evaluating means to evaluate the overall similarity between the known functional protein sequences assigned to the respective segment and the portion of the given protein sequence related to said evaluated segment for each of the segments.  
           [0052]    In a preferred embodiment the inventive apparatus further comprises: overall conservation evaluating means to evaluate the conservation value for each of the segments wherein the conservation value rates the occurrence of conserved amino acids within the evaluated segment.  
           [0053]    The present invention provides a method for the detection of a—so far—unknown functional protein sequence within a given protein sequence having a number of amino acid residues. It is provided that the given protein comprises an amino acid sequence (also referred to herein as protein sequence), wherein functional sites such as phosphorylation sites shall be predicted. The term unknown functional (protein) sequence as used herein shall mean that a given sequence comprises a site, i.e. one or more amino acid residues, which is functional, preferably in vivo, whereby the fact that it is functional is not known prior to the application of the present method. In contrast to this a known functional (protein) sequence is a sequence comprising a site, i.e. one or more amino acid residues, which is functional, preferably in vivo, whereby the fact that it is functional is known prior to the application of the present method. As used herein, the term functional means post-translational processing, protein sorting, protein function etc. Therefore functional sites can be cleavage sites (protease), phosphorylation and other modification sites (protein kinase etc.), ATP binding sites, signal sequences (signal recognition particle), localization signals, DNA binding sites (DNA), Ligand binding sites (ligands), catalytic sites etc.  
           [0054]    Further, a number of known functional protein sequences having a number of contiguous amino acids is provided wherein said known functional protein sequences include proven or confirmed functional sites. For each of said functional protein sequences a resemblance score between the known functional protein sequence and the portion of said given protein sequence to be analysed at one or more alignment positions of the given protein sequence to be analysed is evaluated. The known functional protein sequences and their alignment positions are selected if said resemblance scores exceed a minimum resemblance threshold. According to the alignment position each of the respective known functional protein sequences is designed into a segment wherein the segment is defined by said one or more alignment positions. For each of the segments the overall similarity between the known functional protein sequences assigned to the respective segment and the portion of the given protein sequence related to said evaluated segment is evaluated.  
           [0055]    The method of the present invention allows to automatically construct models of known functional protein sequences which are highly similar to the functional sites to be detected. According to the present invention the prediction is done by the model construction, while in the prior art models are built in advance and applied later.  
           [0056]    The method of the present invention overcomes the inaccuracy evolving from the prediction appearing from the short length of the known functional protein sequences and the functional protein sequences to be found. The case-based model construction allows a high degree and sensitivity of evaluation.  
           [0057]    In view of their inventive method it is no longer necessary to maintain numerous predefined different models of binding sites because according to the method of the present invention case-based models can be automatically constructed.  
           [0058]    The case-based model construction is only controlled by a few specific parameters that allow to obtain predictions with constant sensitivity and specificity. The specific parameters are applied in the same manner for all models which results in predictions of constant accuracy. In contrast to this, all models of the prior art are constructed in different manners at different times by different users. Accordingly, different independent users of such a model are not able to find out the parameters on which the former prediction method is based and are therefore not able to get or rely on the same parameters for applying the model.  
           [0059]    Also, the invention solves several of the currently existing problems in the art:  
           [0060]    overcoming the limitations caused by the shortness of phosphorylation sites,  
           [0061]    maintaining many predefined different models of binding sites,  
           [0062]    obtaining highly sensitive predictions, and  
           [0063]    obtaining predictions with a constant sensitivity and specificity.  
           [0064]    Further embodiments of the present invention may be taken from the dependent claims.  
           [0065]    Preferably, the alignment positions of one of said known functional protein sequences are selected if the resemblance score of one of said known functional proteins sequence has a maximum resemblance score wherein the maximum resemblance score is determined by the maximum value of all resemblance scores at all alignment positions of one known functional sequence. So a smaller number of aligned known functional protein sequences is selected with the given protein sequence for further processing. This increases the accuracy of prediction and the processing speed but may also have the effect that less unknown functional sites are found, resulting in more distinct prediction results.  
           [0066]    According to another preferred embodiment of the present invention the evaluation of said resemblance scores at one or more alignment positions includes the evaluation of said resemblance scores for all alignment positions. This will be preferred if no pre-selection of specific alignment positions to be analysed is made or can reasonably be made.  
           [0067]    In a preferred embodiment said selected known functional protein sequences will be assigned to the same segments if the selected alignment positions assigned to known functional protein sequences are equal. This allows to further increase the accuracy of the prediction methods. It also speeds up processing because functional protein sequences which are aligned at a single and at a specific position of said given protein sequence, can be discarded and, thus, are no longer involved in further processing.  
           [0068]    It may also be possible to assign said selected known functional protein sequences to the same segment if their selected alignment positions are within a predetermined segmentation range. This allows to assign more selected known functional protein sequences to one segment, thereby providing a segment which has a sufficient support, i.e. more than a specific number of known functional protein sequences are assigned to one segment.  
           [0069]    Preferably the evaluation of the overall similarity between the known functional protein sequences assigned to the respective segment and the portion of the given protein sequence ups related to said evaluated segment is performed by creating a matrix. For each of the segments the respective matrix is created containing the number of occurrences of each amino acid at a specific position of said given protein sequence aligned with the respective segment. For each of said matrices m the overall similarity is evaluated according to the following formula:  
         overallsim   :=       overall_similarity                   (     ups   ,   m     )       :=       ∏     l   =   1     s                       (       p   lAl       p   lO       )     .           ,                         
 
           [0070]    wherein s is the length of the portion of the protein sequence to be analysed,  
           [0071]    wherein p lAl  is the number of occurrences of the specific amino acid at a specific position l of said given protein sequence aligned with the respective segment,  
           [0072]    wherein p lO  is the number of occurrences of the most frequent amino acid at the position s of the given protein sequence to be analysed.  
           [0073]    This allows to evaluate the overall similarity related to each of the segments in a fast and easy manner. The overall similarity is calculated using the matrix m in which the number of occurrences of each amino acid at each of the positions s of the given protein sequence lps to be analysed is included. The overall similarity is evaluated by the product of the number of occurrences of the respective amino acids of the given protein sequence lps at each position to be analysed divided by the product of the maximum number of occurrences of any of the amino acids at every position of the given protein sequence to be analysed. Thereby it is possible to determine an overall similarity taking into account all known functional protein sequences which are similar to the portion of the given protein sequence lps.  
           [0074]    It is preferred to determine a conservation value for each of said segments rating the occurrence of the conserved amino acids within the evaluated segment using the formula:  
         C   1     =         log   2          (   20   )       +       ∑   lA                    p     1      A       *       log   2          (     p     1      A       )                     conservation   :=       1   /   s     *       ∑   l                  C   1                               
 
           [0075]    wherein p lA  denotes the evaluated probability of the occurrences of the specific amino acid A in the the respective column l of said matrix m, and  
           [0076]    wherein C l  denotes the conservation of column l in the matrix (p lA ) with the length s of the unknown protein sequence to be analysed. The sum covers all amino acids in the respective column l of the matrix. The calculated column conservation C l  describes the certainty of occurrence of only one amino acid in column l of the matrix. From the single C l  the matrix conservation conservation is derived as the average over all columns l from 1 to s. The matrix conservation conservation represents the confidence of the matrix provided for the prediction, i.e. the likelihood or reliability that the matrix represents a functional site.  
           [0077]    The method of the present invention can be advantageously applied for predicting phosphorylation sites in a given protein sequence wherein the known functional protein sequences containing proven phosphorylation sites are used. This is especially preferred as the phosphorylation sites are small and thereby not predictable with convenient accuracy using methods according to the prior art as described before.  
           [0078]    According to another aspect of the present invention an apparatus for detection of an unknown functional protein sequence within a given protein sequence is provided. The apparatus comprises means for evaluating a resemblance to evaluate a resemblance score between the known functional protein sequence and the portion of said given protein sequence to be analysed at one ore more alignment positions for each of said functional protein sequences. The apparatus further comprises selecting means to select the known functional protein sequence and their alignment positions, if said resemblance scores exceed a minimum resemblance threshold. To assign each of the selected known functional protein sequences to a segment according to their alignment position an assigning means is provided wherein said segment is defined by said one or more alignment positions. By providing an overall similarity evaluation means the overall similarity between the known functional protein sequences assigned to the respective segment and the portion of the given protein sequence related to said evaluated segment can be evaluated f or each of the segments.  
           [0079]    The apparatus of the present invention allows the performing of the inventive method as disclosed herein and can be realized by a standard computer running a computer program code establishing the elements of the apparatus.  
           [0080]    It is to be understood that the annotation made to a part or segment of a given protein sequence to be a functional site as obtained by the inventive method may be further verified. Such verification can be done by various experimental procedure such as further in silico, in vivo, in vitro and/or in situ testing. Once this annotation is available the ones skilled in the art may use it for, e.g., target validation, drug design, diagnostic purposes, therapeutic purposes, metabolic design, gene therapy, and basic research.  
           [0081]    As used herein the term “to evaluate a value” shall preferably mean to determine a value.  
           [0082]    The method and apparatus of the present invention are now explained and illustrated in more detail especially by the following figures and examples relating to the prediction of phosphorylation sites. It is to be acknowledged that from the figures and the examples further features, embodiments and advantages of the present invention may be taken. 
       
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS  
       [0083]    [0083]FIG. 1 illustrates the concept of lps, pps, ups, apps, block and segment. Proven phosphorylation sites (pps) are first aligned to the longer protein sequence (lps) yielding aligned proven phosphorylation sites (apps) corresponding to the unknown phosphorylation sites (ups 1-4) where ups 1-2 and ups 3-4 are at exactly the same position in lps in this example. Then the apps are split by their respective function into blocks and then split by position into segments. Such function may be or may be related to, preferably in the hierarchical system as preferably used in the method according to the present invention, cleavage sites (protease), phosphorylation and other modification sites (protein kinase etc.), ATP binding sites, signal sequences (signal recognition particle), localization signals, DNA binding sites (DNA), Ligand binding sites (ligands), catalytic sites and the like. This results in apps with the same function at the same position.  
         [0084]    [0084]FIG. 2 depicts the flow starting with pps and resulting in matrices. The pps are aligned to lps resulting in apps. Apps are grouped by their function and assigned to segments according to their position. Matrices are built from the resulting segments.  
     
    
     DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT  
       [0085]    The method and the apparatus of the present invention uses a database D (e.g. the Phosphobase [Kreegipuu A., Blom N. and Brunak S. (1999), PhosphoBase, a database of phosphorylation sites: release 2.0., Nucleic Acids Res 27(1), 237-239]) of biologically proven phosphorylation sites (pps) to predict unknown phosphorylation sites (ups) in a given longer protein sequence (lps) u. The method includes the steps listed below. The principle is applicable for other kinds of short functional sequence elements to be detected in longer protein sequences to be analysed.  
         [0086]    1. Preprocessing: pps are extracted from D and grouped by the three possible acceptor residues (tyrosine, serine and threonine) and subcategorised by kinase classes (e.g. every PKC phosphorylation site is assigned to one category that is a subclass of serine).  
         [0087]    2. Alignment: All pps are aligned to the protein sequence lps to be analysed yielding a set of aligned pps (apps).  
         [0088]    3. Segmentation: The aligned known binding sites (apps) taken from the database D are grouped in segments G according to their function (i.e. acceptor residue and kinase class) and position relative in lps. Each segment of G, containing apps of one function and a similar position, ideally predict one single unknown phosphorylation site ups in the longer protein sequence lps under evaluation.  
         [0089]    4. Model construction: All apps contained in one segment are hierarchically aligned leading to a set of matrices in each segment. Each matrix comprises a subset of the apps in the segment under study. All apps of those subsets are highly similar to each other, the according matrix is highly similar to the ups (i.e. the consensus, described by the matrix, resembles the ups) and the matrix is highly conserved (the variance in each column of the matrix is low).  
         [0090]    In the following, the above mentioned steps are described in more detail.  
         [0091]    The alignment step is performed aligning all known phosphorylation sites pps with the given protein sequences lps at each possible position s. The known binding sites pps are so aligned to the unknown protein sequence ups. An evaluation of the resemblance is performed by introducing a score which constantly rises when successive amino acids of the analysed sequence are matching with the phosphorylation site. This resemblance score is then assigned to each of the amino acids of the analysed sequence. The evaluation ensures that a contiguous sequence of amino acids of length l is higher than two runs of length a and b with l=a+b. The resemblance is the sum of the scores of every position of the amino acids. With n as the length of the known phosphorylation site and the unknown lbs ups one gets:  
         resemblance (u, s):=Σ i=1 . . . n η*SMA  
         [0092]    where SMA is the number of successive matching amino acids.  
         [0093]    Example (η=2):  
                                   Examined   L K L A S P E L E L K   (SEQ. ID NO:1)           Sequence ups:               Known phospho-   E K L A S K E L E V D   (SEQ. ID NO:2)       rylation site       pps:               SMA   0 4 4 4 4 0 3 3 3 0 0               SMA * η   0 8 8 8 8 0 6 6 6 0 0                                             SMA = 4    SMA = 3          
 
         [0094]    As the first examined amino acid is non-matching a SMA value of “0” is assigned to the first position. For the first matching portion of the examined sequence the SMA equals 4 as four successive matching amino acids “KLAS” are detected before the next examined amino acid is non-matching. Thus to each of the matching amino acid residue a SMA number of 4 is assigned. The next occurring sequence of matching amino acids has a length of 3 so a SMA value of 3 is assigned to each of the matching amino acids.  
         [0095]    The total resemblance score according to the above given formula is the sum of all SMA values weighted by the η value of “2” which is user defined and can have other values.  
         [0096]    For the upper example the total resemblance score is 4*8+3*6=32+18=40. This step results in a set P of aligned phosphorylation sites (apps) wherein the known phosphorylation sites are associated with a resemblance score. To reduce the number of elements in set P only elements whose resemblance score is exceeding a given threshold resemblance may be considered and added to set P. This allows to control the number of elements in P and to gain processing speed for the following steps. The threshold resemblance is user defined and set to control the number of elements of set P for the following steps.  
         [0097]    To construct matrices the set P has to be sorted by function and position. The function is classified regarding the two levels shown in Table 1.  
                                 TABLE 1                           Classification of phosphorylation sites            Level   Name   Criterion   Example               1   Class   Acceptor residues   S-14       2   Subclass   Kinase   PKC                  
 
         [0098]    The elements of set P are assigned to different blocks B according to the respective levels.  
         [0099]    The alignment pεP of the unknown functional protein sequence u and a binding site is described by the pair &lt;site_id, site_class&gt;.  
         [0100]    Example: The set P={&lt;T0001, 2.1&gt;, &lt;T0002, 1.1&gt;, &lt;T0003, 2.2&gt;, &lt;T(004, 2.1&gt;, &lt;T0005, 1.2&gt;} yields to the blocks B 1 ,B 2  with B 1 ={&lt;T0002, 1.1&gt;, &lt;T0005, 1.2&gt;} and B 2 ={&lt;T0001, 2.1&gt;, &lt;T0004, 2.1&gt;, &lt;T0003, 2.2&gt;}.  
         [0101]    Each block B 1 , B 2  is split into segments G wherein the position of each pεP is used to assign the element pairs of each block to the respective segments according to the position in the unknown functional protein sequence u to be analysed. If the respective positions p 1 , p 2  εB of one of the blocks are distanced to each other for more than half the desired matrix width p 1  and p 2  are put into separate segments G otherwise they are assigend to the same segment G. Therefore, each segment G comprises the element pairs including the positions of possible binding sites that are bound to similarly structured domains and found at similar positions.  
         [0102]    In a next step matrices have to be constructed. The construction of the matrices is done using a gap free heuristic alignment. Gap free heuristic alignment means that no gaps in the matrix construction are considered. A heuristic algorithm is used because an optimal alignment is NP-complete. Gaps cannot be taken into consideration because of the short length of the phosphorylation sites. The heuristic alignment aligns the phosphorylation sites of each of the segments G in the order of the resemblance score of each found possible phosphorylation site. Phosphorylation sites at the same position of the given protein sequence are assigend to one matrix while several matrices are constructed if the found phosphorylation sites partially overlap each other or do not overlap.  
         [0103]    Adopting the strategy of hierachical clustering, possible phosphorylation sites of G are successively merged to a large matrix until the matrix fulfills specific requirements, i.e. the matrix&#39;s average conservation value should be above a given minimum conservation min_con, the matrix should have a minimum overall_similarity to u min_sim, and there should be a minimum number of sites min_sup in one of the matrices to support the sequence.  
         [0104]    The conservation value is calculated by the average information content given by:  
                 C   1     =         log   2          (   20   )       +       ∑   lA                    p     1      A       *       log   2          (     p     1      A       )                    
          conservation   :=       1   /   s     *       ∑   l                  C   1                   Eq   .              1                               
 
         [0105]    Here C l  denotes the conservation of column l in the matrix (p lA ) with the length s of the unknown protein sequence to be analysed. The sum covers all amino acids in the respective column l of the matrix. The calculated column conservation C, describes the certainty of occurrence of only one amino acid in column l of the matrix. From the single C l  the matrix conservation is derived as the average over all columns l from 1 to s.  
         [0106]    The overall similarity between matrix and ups is determined as follows.  
         [0107]    The overall similarity between the matrix and ups is calculated as disclosed in: Berg, O. G. and P. H. von Hippel 1987  J Mol Biol  193:723-750.  
         [0108]    The reduction in free binding energy is:  
                 r        (   u   )       :=           ∑     i   =   1     s                       E     1      A                     with       -       E     1      B       *   λ       =       ln                   (       p   lA       p   lO       )                   with                 λ     =   1         ,           Eq   .              2                               
 
         [0109]    where E lA  is the binding energy for a single amino acid. The probability p lA  is given by the number of the amino acid corresponding the unknown functional protein sequence ups to be analysed. p 10  is largest value in column l, i.e. the largest number of occurrences of one of the possible amino acids, and reflects the consensus sequence. This leads to the following binding energy for ups:  
         energy ( ups, m ):= K   0   *exp (− r ( ups )),  Eq. 3  
         [0110]    where K 0  is a binding constant and matrix m=(p lA ). In general K 0  is assumed to equal 1 if not known. Using sim=energy(ups, m) leads to the calculation for the overall similarity sim of the matrix m related to an unknown partial protein sequence ups having a length s and with p lO  as a maximum of a column as follows:  
             sim   :=       overall_similarity                   (     ups   ,   m     )       :=       ∏     l   =   1     s                       (       p   lAl       p   lO       )     .                 Eq   .              4                               
 
         [0111]    The matrix is then constructed according to the following flow program. Each found phosphorylation site is assigned to an existing matrix or to a different matrix. Matrices which are poorly supported as determined by a users variable min_sup are discarded after finishing the assignment of all found possible phosphorylation sites.  
       Method of Matrix Construction  
       [0112]    [0112]                                                   M := {generate_matrix(p)}, p is first apps of segment            for all other p ∈ G {             for all m ∈ M {              if (p and m overlap) and (p not already used for m) {               m′ :=m  merged with p               if (overall_similarity(u,m’)&gt;=min_sim) and               (conservation(m′) &gt;= min_cons) {                m := m′ }               else {               M := M ∪ generate_matrix(p) }}}}           for all m ∈ M            if support(m) &lt; min_sup [             discard m }}                        
       Method of Matrix Generation  
       [0113]    [0113]                                   generate_matrix(p)        P :={set of apps in matrix } ∪ p        m′ := empty matrix        for all p’ ∈ P {         m′ :=m′ extended by p′ }        m := window with width matrixlen with highest conservation in m′                    
         [0114]    The matrix m′ emerges from the already generated matrix m extended by the element pair at position p. The width of each matrix is chosen by a parameter and normally is the same for each matrix although phophorylation sites can differ in length. It is also possible to choose different width for the matrices.  
         [0115]    As a minimal conservation is required for each of the matrices a parameter min_cons is introduced which assures that a minimal amount of information is available to predict the existence of a binding site. Accordingly, the parameter min sim denotes the minimal required similarity and the parameter min sup denotes the minimal required support of each of the matrices.  
         [0116]    A new matrix is generated if the overall similarity or conservation value of an existing matrix m would decrease by merging p to m. Hence, overall similarity and conservation values are evaluated each time a new element pair is merged. The new matrix (line 9) is added to M. At last the algorithm for generating the extended matrix: generate_matrix(p) is described.  
         [0117]    The variable input parameters of the total method are:  
         [0118]    η: used for adjusting the resemblance score in “alignment” 
         [0119]    matrixlen: desired width of matrix, used in “matrix construction”.  
         [0120]    The following parameters are used as minimum thresholds:  
         [0121]    pairsim: minimum threshold resemblance score for selecting known phosphorylation sites  
         [0122]    th: minimum threshold for creating a new segment, used in the step of “segmentation” 
         [0123]    min_sim: minimum similarity between matrix and the portion of the given protein sequence lps to be analysed, i.e. unknown functional protein sequence ups,  
         [0124]    min_sup: minimum support, denoting the number of known phosphorylation sites contained in one matrix  
         [0125]    min_cons: minimum conservation of matrices, used in “matrix construction” 
         [0126]    mat_overlap: minimum overlap between an existing matrix and a known phosphorylation site  
         [0127]    Both variable input parameters and minimum threshold parameters may be user-defined or fixed.  
         [0128]    Input data:  
         [0129]    Library of known phosphorylation sites (hierarchically structured)  
         [0130]    lps: longer protein sequence to be analysed  
         [0131]    In the following an example for predicting phosphorylation sites according to the present invention is described in detail.  
       EXAMPLE 1  
       [0132]    The protein sequence  
         [0133]    u=LVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYD (SEQ ID NO: 3) will be analysed in this example by aligning known phosphorylation sites. Each letter represents a type of amino acid. Therefore the following 19 proven phosphorylation sites, denominated by 051-A, A002-F, A002-C, A011-A, B110-B, A002-D, A065-B, A071-B, A002-I, A026-B, A039-A, A002-J, B281-C, B020-A, B012-A, B319-A, B054-A, B012-B, B046-B from the database, e.g. SWISS-PROT, are aligned to u. For each site the position in u is given by the variable xp. The variable sim (resemblance) shows the resemblance score calculated with Eq. 4.  
                                                     seq:           LVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYD            xp = 567   xb = 0   sim = 12                   1.3.0       +A051-A   fpvsysssg   (SEQ ID NO:4)               xp = 573   xb = 0   sim = 18       1.3.0       +A002-F   sdggymdms   (SEQ. ID NO:5)               xp = 574   xb = 0   sim = 162       1.3.0       +A002-C   dgheyiyvd   (SEQ. ID NO:6)               xp = 574   xb = 0   sim = 32       1.3.0       +A011-A   kgheytnik   (SEQ. ID NO:7)               xp = 574   xb = 0   sim = 18       1.3.0       +B110-B   kaEeyilkk   (SEQ. ID NO:8)               xp = 576   xb = 0   sim = 162       1.3.0       +A002-D   heyiyvdPm   (SEQ. ID NO:9)               xp = 576   xb = 0   sim = 12       1.3.0       +A065-B   nnyVyidPt   (SEQ. ID NO:10)               xp = 576   xb = 0   sim = 12       1.3.0       +A071-B   nnyVyidPt               xp = 584   xb = 0   sim = 18       1.3.0       +A002-I   ymapydnyv   (SEQ. ID NO:11)               xp = 584   xb = 0   sim = 12       1.3.0       +A026-B   mmtpyvvtr   (SEQ. ID NO:12)               xp = 587   xb = 0   sim = 18       1.3.0       +A002-J   pydnyvpsA   (SEQ. ID NO:13)               xp = 556   xb = 0   sim = 18       1.1.0       +B281-C   eslesyein   (SEQ ID NO:14)               xp = 560   xb = 0   sim = 20       1.1.0       +B020-A   maevswkvl   (SEQ ID NO:15)               xp = 566   xb = 0   sim = 16       1.1.0       +B012-A   eiveslsss   (SEQ ID NO:16)               xp = 566   xb = 0   sim = 12       1.1.0       +B054-A   gvrqsrasd   (SEQ ID NO:17)               xp = 568   xb = 0   sim = 16       1.1.0       +B012-B   veslssseE   (SEQ ID NO:18)               xp = 568   xb = 0   sim = 18       1.1.0       +B046-B   lqryssdpt   (SEQ ID NO:19)          
 
         [0134]    Subsequently, all aligned proven phosphorylation sites are grouped by function which are denoted by 1.3.0 or 1.1.0 in the given example. Grouping by level 2 leads to two functional blocks: aligned proven phosphorylation sites of the groups 1.3.0 and 1.1.0. As the further processing for each functional block is the same only the further processing of block 1.3.0. is demonstrated.  
         [0135]    The aligned proven phosphorylation sites (apps) of block 1.3.0. are grouped into positional segments in the next step. This is done by:  
         [0136]    (1) sorting all apps by their position xp.  
         [0137]    (2) measuring the distance d between subsequently following apps1 and apps2.  
         [0138]    (3) if d exceeds a certain threshold th than a new positional segment is created and apps2 is its first member.  
         [0139]    This shows the following example of the first two apps at positions xp=567 and xp=573:  
                                               xp = 567   sim = 12                   1.3.0   A051-A   fpvsysssg                       xp = 573   sim = 18           1.3.0   A002-F   sdggymdms          
 
         [0140]    Their positions (given by their xp coordinates) differ by 573-567=8 letters. Assuming a user defined threshold th of 4, which for example represents half the desired matrix width, a first segment G1 is created including the apps A051-A/xp=567 and a second segment G2 is created including the apps A002-F/xp=573. Next the apps A002-F/xp=573 and A002-C/xp=574 are compared.  
                                               xp = 573   sim = 18                   1.3.0   A002-F   sdggymdms                       xp = 574   sim = 162           1.3.0   A002-C   dgheyiyvd          
 
         [0141]    Their positions differ by 573-571=2 letters. Assuming again a threshold th of 4 makes A002-C/xp=574 fall into the same segment G2 of the apps A002-F/xp=573 now containing two apps. In the same way the following apps are compared.  
                                               xp = 574   sim = 162                   1.3.0   A002-C   dgheyiyvd                       xp = 574   sim = 32           1.3.0   A011-A   kgheytnik          
 
         [0142]    Their positions xp differ by 0 enhancing G2 (which is the respective segment for positions close to xp=573) to three apps now which are A002-F/xp=573, A002-X/xp=574, A011-A/xp=574. By this method the following apps are added to G2:  
                                               xp = 574   sim − 18                   1.3.0   B110-B   kaEeyilkk                       xp = 576   sim = 162           1.3.0   A002-D   heyiyvdPm                       xp = 576   sim = 12           1.3.0   A065-B   nnyVyidPt                       xp = 576   sim = 12           1.3.0   A071-B   nnyVyidPt          
 
         [0143]    leading to the segment G2 which finally contains seven apps: {A002-F/xp=573, A002-X/xp=574, A011-A/xp=574, B110-B/xp=574, A002-D/xp=576, A065-B/xp=576, A071B/xp=576}.  
         [0144]    As a next step the apps A071-B/xp=576 and A002-I/xp=584 will be compared:  
                                               xp = 576   sim = 12                   1.3.0   A071-B   nnyVyidPt                       xp = 584   sim = 18           1.3.0   A002-I   ymapydnyv          
 
         [0145]    Their distance in positions is 8. As 8 exceeds the given threshold of 4 a new segment G3 is created containing the apps A002-I/xp=584.  
         [0146]    Next, the step of the matrix generation is described.  
         [0147]    As an example matrices are constructed from segment G2. First, all apps from G2 are sorted by their sim value which is their similarity to the protein sequence to be analysed yielding the following order of apps:  
                                               xp = 574   sim = 162                   1.3.0   A002-C   dgheyiyvd                       xp = 576   sim = 162           1.3.0   A002-D   heyiyvdPm                       xp = 574   sim = 32           1.3.0   A011-A   kgheytnik                       xp = 573   sim = 18           1.3.0   A002-F   sdggymdms                       xp = 574   sim = 18           1.3.0   B110-B   kaEeyilkk                       xp = 576   sim = 12           1.3.0   A065-B   nnyVyidPt                       xp = 576   sim = 12           1.3.0   A071-B   nnyVyidPt          
 
         [0148]    From the first apps an initial matrix is build. Thus the initial matrix for G2 is constructed from:  
                                               xp = 574   sim = 162                   1.3.0   A002-C   dgheyiyvd          
 
         [0149]    The matrix is constructed with a width specified by the parameter matrixien which is user defined or given by the number of amino acids of the known phosphorylation sites, assumed in this example to be 9 amino acids. So the resulting initial matrix M1 has the following number of occurrences, denoted M1.fA, M1.f, . . . :  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M1.fA   0   0   0   0   0   0   0   0   0       M1.fR   0   0   0   0   0   0   0   0   0       M1.fN   0   0   0   0   0   0   0   0   0       M1.fD   1   0   0   0   0   0   0   0   1       M1.fC   0   0   0   0   0   0   0   0   0       M1.fQ   0   0   0   0   0   0   0   0   0       M1.fE   0   0   0   1   0   0   0   0   0       M1.fG   0   1   0   0   0   0   0   0   0       M1.fH   0   0   1   0   0   0   0   0   0       M1.fI   0   0   0   0   0   1   0   0   0       M1.fL   0   0   0   0   0   0   0   0   0       M1.fK   0   0   0   0   0   0   0   0   0       M1.fM   0   0   0   0   0   0   0   0   0       M1.fF   0   0   0   0   0   0   0   0   0       M1.fP   0   0   0   0   0   0   0   0   0       M1.fS   0   0   0   0   0   0   0   0   0       M1.fT   0   0   0   0   0   0   0   0   0       M1.fW   0   0   0   0   0   0   0   0   0       M1.fY   0   0   0   0   1   0   1   0   0       M1.fV   0   0   0   0   0   0   0   1   0                  
 
         [0150]    M1 has the leftmost position of its only apps A002-C/xp=574 which is 574. Following the next apps A002-D/xp=576 
                                               xp = 576   sim = 162                   1.3.0   A002-D   heyiyvdPm          
 
         [0151]    is examined for enhancing M1. The distance between the position xp=576 of A002-D/xp=576 and the leftmost position of the matrix 574 is calculated to be 2. So A002-D/xp=576 overlaps the matrix by 6 letters. As the matrix has a width of 9 amino acids a complete overlap of 9 amino acids is required, which is not fulfilled here. Therefore A002-D/xp=576 is not used in M1. Instead another matrix M2 is generated including A002-D/xp=576 and related to the respective portion of the unknown functional protein sequence u  
                                               1.3.0   A002-D   heyiyvdPm              
 
         [0152]    leading to M2:  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M2.fA   0   0   0   0   0   0   0   0   0       M2.fR   0   0   0   0   0   0   0   0   0       M2.fN   0   0   0   0   0   0   0   0   0       M2.fD   0   0   0   0   0   0   1   0   0       M2.fC   0   0   0   0   0   0   0   0   0       M2.fQ   0   0   0   0   0   0   0   0   0       M2.fE   0   1   0   0   0   0   0   0   0       M2.fG   0   0   0   0   0   0   0   0   0       M2.fH   1   0   0   0   0   0   0   0   0       M2.fI   0   0   0   1   0   0   0   0   0       M2.fL   0   0   0   0   0   0   0   0   0       M2.fK   0   0   0   0   0   0   0   0   0       M2.fM   0   0   0   0   0   0   0   0   1       M2.fF   0   0   0   0   0   0   0   0   0       M2.fP   0   0   0   0   0   0   0   1   0       M2.fS   0   0   0   0   0   0   0   0   0       M2.fT   0   0   0   0   0   0   0   0   0       M2.fW   0   0   0   0   0   0   0   0   0       M2.fY   0   0   1   0   1   0   0   0   0       M2.fV   0   0   0   0   0   1   0   1   0                  
 
         [0153]    M2 has the leftmost position of its only apps A002-D/xp=576 which is 576. As the next of the apps of G2 the apps A011-A/xp=574 is examined to merge with each of the existing matrices M1 and M2.  
                                               xp = 574   sim = 32                   1.3.0   A011-A   kgheytnik          
 
         [0154]    As the apps A011-A/xp=574 completely overlaps the matrix M1, it is potentially merged to a temporary new matrix M1′ now containing the two apps:  
                                               xp = 574   sim = 162                               1.3.0   A002-C   dgheyiyvd                       xp = 574   sim = 32                       1.3.0   A011-A   kgheytnik          
 
         [0155]    [0155]                                                                   Position   1   2   3   4   5   6   7   8   9                   M1′.fA   0   0   0   0   0   0   0   0   0       M1′.fR   0   0   0   0   0   0   0   0   0       M1′.fN   0   0   0   0   0   0   1   0   0       M1′.fD   1   0   0   0   0   0   0   0   1       M1′.fC   0   0   0   0   0   0   0   0   0       M1′.fQ   0   0   0   0   0   0   0   0   0       M1′.fE   0   0   0   2   0   0   0   0   0       M1′.fG   0   2   0   0   0   0   0   0   0       M1′.fH   0   0   2   0   0   0   0   0   0       M1′.fI   0   0   0   0   0   1   0   1   0       M1′.fL   0   0   0   0   0   0   0   0   0       M1′.fK   1   0   0   0   0   0   0   0   1       M1′.fM   0   0   0   0   0   0   0   0   0       M1′.fF   0   0   0   0   0   0   0   0   0       M1′.fP   0   0   0   0   0   0   0   0   0       M1′.fS   0   0   0   0   0   0   0   0   0       M1′.fT   0   0   0   0   0   1   0   0   0       M1′.fW   0   0   0   0   0   0   0   0   0       M1′.fY   0   0   0   0   2   0   1   0   0       M1′.fV   0   0   0   0   0   0   0   1   0                    
         [0156]    For M1′ the average conservation is 87%. The conservation indicates the probability of the occurrence of a conserved amino acid at a specific position. The average conservation indicates the average probability of the occurrence of conserved amino acids in the examined sequence. The calculation of conservation is shown below.  
         [0157]    For similarity and average conservation the thresholds min_sim=1 and min_cons=75%. are assumed. The threshold min_sim is evaluated if at least 3 sites are incorporated in the matrix, i.e. if the minimum support number min sup of known phosphorylation sites apps in one matrix is achieved. If the average conservation value and the overall similarity exceeds both thresholds, M1 is replaced by M1′ [line 7 of Method 1 matrix_construction].  
         [0158]    In the same manner, the apps (B110-B/xp=574)  
                                               xp = 574   sim = 18                   1.3.0   B110-B   kaEeyilkk          
 
         [0159]    is merged to M1 resulting in the final matrix M1 which includes the known phosphorylation sites apps  
                                               xp = 574   sim = 162                               1.3.0   A002-C   dgheyiyvd                       xp = 574   sim = 32                       1.3.0   A011-A   kgheytnik                       xp = 574   sim = 18                       1.3.0   B110-B   kaEeyilkk          
 
         [0160]    and leading to the matrix:  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M1.fA   0   1   0   0   0   0   0   0   0       M1.fR   0   0   0   0   0   0   0   0   0       M1.fN   0   0   0   0   0   0   1   0   0       M1.fD   1   0   0   0   0   0   0   0   1       M1.fC   0   0   0   0   0   0   0   0   0       M1.fQ   0   0   0   0   0   0   0   0   0       M1.fE   0   0   1   3   0   0   0   0   0       M1.fG   0   2   0   0   0   0   0   0   0       M1.fH   0   0   2   0   0   0   0   0   0       M1.fI   0   0   0   0   0   2   0   1   0       M1.fL   0   0   0   0   0   0   1   0   0       M1.fK   2   0   0   0   0   0   0   1   2       M1.fM   0   0   0   0   0   0   0   0   0       M1.fF   0   0   0   0   0   0   0   0   0       M1.fP   0   0   0   0   0   0   0   0   0       M1.fS   0   0   0   0   0   0   0   0   0       M1.fT   0   0   0   0   0   1   0   0   0       M1.fW   0   0   0   0   0   0   0   0   0       M1.fY   0   0   0   0   3   0   1   0   0       M1.fV   0   0   0   0   0   0   0   1   0                  
 
         [0161]    M1 has a conservation value of 80% as calculated as explained below. The overall similarity score of M1 to the unknown protein sequence u is 25%, calculated by Eq. 4. In the same manner the second matrix M2 is generated with  
                                               xp = 576   sim = 162                               1.3.0   A002-D   heyiyvdPm                       xp = 576   sim = 12                       1.3.0   A065-B   nnyVyidPt                       xp = 576   sim = 12                       1.3.0   A071-B   nnyVyidPt          
 
         [0162]    leading to  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M2.fA   0   0   0   0   0   0   0   0   0       M2.fR   0   0   0   0   0   0   0   0   0       M2.fN   2   2   0   0   0   0   0   0   0       M2.fD   0   0   0   0   0   0   3   0   0       M2.fC   0   0   0   0   0   0   0   0   0       M2.fQ   0   0   0   0   0   0   0   0   0       M2.fE   0   1   0   0   0   0   0   0   0       M2.fG   0   0   0   0   0   0   0   0   0       M2.fH   1   0   0   0   0   0   0   0   0       M2.fI   0   0   0   1   0   2   0   0   0       M2.fL   0   0   0   0   0   0   0   0   0       M2.fK   0   0   0   0   0   0   0   0   0       M2.fM   0   0   0   0   0   0   0   0   1       M2.fF   0   0   0   0   0   0   0   0   0       M2.fP   0   0   0   0   0   0   0   3   0       M2.fS   0   0   0   0   0   0   0   0   0       M2.fT   0   0   0   0   0   0   0   0   2       M2.fW   0   0   0   0   0   0   0   0   0       M2.fY   0   0   3   0   3   0   0   0   0       M2.fV   0   0   0   2   0   1   0   0   0                  
 
         [0163]    with an overall_similarity of 3.125% and a conservation of 88%.  
         [0164]    A third matrix M3 which is not shown here is constructed only from  
                                               xp = 573   sim = 18                   1.3.0   A002-F   sdggymdms          
 
         [0165]    The support of this matrix M3 is 1 and does not exceed the given minimum support threshold of 3 and is therefore too low so that the matrix M3 is discarded in a support checking step following the matrix generation. The matrices M1 and M2 include a higher number of assigned known phosphorylation sites apps and are retained because their support exceeds the given minimum support threshold.  
         [0166]    Finally, the following results are achieved:  
         [0167]    Protein sequence to be analysed:  
                                             LVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYD                Phase 4       (SEQ. ID NO:20)           1.3.0   574  582   DnnEYnnnD               1.3.0   A002-C   DGHEYIYVD               1.3.0   A011-A   KGHEYTNIK               1.3.0   B110-B   KAEEYILKK               ; Sim = 25.0002;   Conservation = 80                       |||||||||                       |||||||||                       |||||||||                       |||||||||                       |||||||||               XX       (SEQ. ID NO:21)       1.3.0   576  584   NNYnYnDPn               1.3.0   A002-D   HEYIYVDPM               1.3.0   A065-B   NNYVYIDPT               1.3.0   A071-B   NNYVYIDPT               ; Sim = 3.12508;   Conservation = 88                       |||||||||                       |||||||||                       |||||||||                       |||||||||                       |||||||||               XX       Segments:       1.3.0   574  584   = = = phospho =          
 
         [0168]    As used herein “phospho” denotes a phosphorylation group or group of phosphorylation sites which consists of all phosphorylation sites which are not comprised in an annotated or named group (such as contained in a databank). Examples for such annotated groups are PKC and PKA.  
         [0169]    The calculation of the conservation value for a given matrix is illustrated for the following example matrix:  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M2.fA   0   0   0   0   0   0   0   0   0       M2.fR   0   0   0   0   0   0   0   0   0       M2.fN   2   2   0   0   0   0   0   0   0       M2.fD   0   0   0   0   0   0   3   0   0       M2.fC   0   0   0   0   0   0   0   0   0       M2.fQ   0   0   0   0   0   0   0   0   0       M2.fE   0   1   0   0   0   0   0   0   0       M2.fG   0   0   0   0   0   0   0   0   0       M2.fH   1   0   0   0   0   0   0   0   0       M2.fI   0   0   0   1   0   2   0   0   0       M2.fL   0   0   0   0   0   0   0   0   0       M2.fK   0   0   0   0   0   0   0   0   0       M2.fM   0   0   0   0   0   0   0   0   1       M2.fF   0   0   0   0   0   0   0   0   0       M2.fP   0   0   0   0   0   0   0   3   0       M2.fS   0   0   0   0   0   0   0   0   0       M2.fT   0   0   0   0   0   0   0   0   2       M2.fW   0   0   0   0   0   0   0   0   0       M2.fY   0   0   3   0   3   0   0   0   0       M2.fV   0   0   0   2   0   1   0   0   0                  
 
         [0170]    For each matrix value the probability is calculated leading to the matrix:  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M2.fA   0   0   0   0   0   0   0   0   0       M2.fR   0   0   0   0   0   0   0   0   0       M2.fN   0, 67   0, 67   0   0   0   0   0   0   0       M2.fD   0   0   0   0   0   0   1   0   0       M2.fC   0   0   0   0   0   0   0   0   0       M2.fQ   0   0   0   0   0   0   0   0   0       M2.fE   0   0, 33   0   0   0   0   0   0   0       M2.fG   0   0   0   0   0   0   0   0   0       M2.fH   0, 33   0   0   0   0   0   0   0   0       M2.fI   0   0   0   0, 33   0   0, 67   0   0   0       M2.fL   0   0   0   0   0   0   0   0   0       M2.fK   0   0   0   0   0   0   0   0   0       M2.fM   0   0   0   0   0   0   0   0   0, 33       M2.fF   0   0   0   0   0   0   0   0   0       M2.fP   0   0   0   0   0   0   0   1   0       M2.fS   0   0   0   0   0   0   0   0   0       M2.fT   0   0   0   0   0   0   0   0   0, 67       M2.fW   0   0   0   0   0   0   0   0   0       M2.fY   0   0   1   0   1   0   0   0   0       M2.fV   0   0   0   0, 67   0   0, 33   0   0   0                  
 
         [0171]    Now the weighted information content of each matrix value I lA  is calculated using the formula:  
           I   lA   p   lA   =*log   10   p   lA .  
         [0172]    Here log 10  instead of log 2  is used which makes no differences in evaluating the matrix.  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M2.fA   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fR   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fN   −0, 12   −0, 12   −0   −0   −0   −0   −0   −0   −0       M2.fD   −0   −0   −0   −0   −0   −0   0   −0   −0       M2.fC   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fQ   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fE   −0   −0, 16   −0   −0   −0   −0   −0   −0   −0       M2.fG   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fH   −0, 16   −0   −0   −0   −0   −0   −0   −0   −0       M2.fI   −0   −0   −0   −0, 16   −0   −0, 12   −0   −0   −0       M2.fL   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fK   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fM   −0   −0   −0   −0   −0   −0   −0   −0   −0, 16       M2.fF   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fP   −0   −0   −0   −0   −0   −0   −0   0   −0       M2.fS   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fT   −0   −0   −0   −0   −0   −0   −0   −0   −0, 12       M2.fW   −0   −0   −0   −0   −0   −0   −0   −0   −0       M2.fY   −0   −0   0   −0   0   −0   −0   −0   −0       M2.fV   −0   −0   −0   −0, 12   −0   −0, 16   −0   −0   −0       87, 98442575   78, 546   78, 546   99, 782   78, 546   99, 782   78, 546   99, 782   99, 782   78, 546                  
 
         [0173]    For each column the to 100% normalized sum of all  
         C   1     =         log   10          (   20   )       +       ∑   lA                    p     1      A       *       log   10          (     p     1      A       )                                   
 
         [0174]    is given. The average conservation value is calculated by:  
       conservation   :=         1   /   20     *       ∑   l                  C   1         =     87   ,   98442575                 %                             
 
         [0175]    As described in Eq. 4 the overall similarity is calculated with:  
       overallsim   :=       overall_similarity                   (     ups   ,   m     )       :=       ∏     l   =   1     s                     (       p   lAl       p   lO       )                               
 
         [0176]    and evaluated for the following matrix and ups=DGHEYIYVD.  
                                                                   Position   1   2   3   4   5   6   7   8   9                   M1.fA   0   1   0   0   0   0   0   0   0       M1.fR   0   0   0   0   0   0   0   0   0       M1.fN   0   0   0   0   0   0   1   0   0       M1.fD   1   0   0   0   0   0   0   0   1       M1.fC   0   0   0   0   0   0   0   0   0       M1.fQ   0   0   0   0   0   0   0   0   0       M1.fE   0   0   1   3   0   0   0   0   0       M1.fG   0   2   0   0   0   0   0   0   0       M1.fH   0   0   2   0   0   0   0   0   0       M1.fI   0   0   0   0   0   2   0   1   0       M1.fL   0   0   0   0   0   0   1   0   0       M1.fK   2   0   0   0   0   0   0   1   2       M1.fM   0   0   0   0   0   0   0   0   0       M1.fF   0   0   0   0   0   0   0   0   0       M1.fP   0   0   0   0   0   0   0   0   0       M1.fS   0   0   0   0   0   0   0   0   0       M1.fT   0   0   0   0   0   1   0   0   0       M1.fW   0   0   0   0   0   0   0   0   0       M1.fY   0   0   0   0   3   0   1   0   0       M1.fV   0   0   0   0   0   0   0   1   0                  
 
         [0177]    The value p lAl  equals the number of occurrence of the amino acid of the respective position in the protein sequence to be analysed.  
         [0178]    The value p lO  is the maximum number of occurrence of one of the amino acids of the respective column, this leads to the following table  
                                                                   Position   1   2   3   4   5   6   7   8   9                   p 1A1     1   2   2   3   3   2   1   1   1       p 1o     2   2   2   3   3   2   1   1   2                  
 
         [0179]    and therefore the similarity is:  
       sim   =       72   288     =     0.25   .                             
 
         [0180]    In the following another example is illustrated.  
       EXAMPLE 2  
       [0181]    The database of proven phosphorylation sites (pps) is hierarchically structured in three levels. The first level defines the kind of post-translational-modification (here 1=phosphorylation sites). The second level refers to the phosphorylated residue (1=S, 2=T, 3=Y). The third level defines the acting kinase (1.1.2=Phosphorylation, at S, PKA is acting). A zero is used to indicate, if the kinase is not known (1.1.0=phosphorylation at S of an unknown kinase). In the following excerpts of the total database are shown. Each known phosphorylation site has its name extended, describing its the database origin (&gt;B034-A16@P11217 — 15 indicates that B034-A16 stems from SWISS-PROT database, protein P11217, aminoacid 15).  
                                                                           PKA                   1.1.2.           &gt; B034-A16@P11217_15           KQGSGRGL   (SEQ ID NO:22)                       &gt; B034-A02@P11217_15           KRKQISVRGL   (SEQ ID NO:23)                       &gt; B034-A17@P11217_15           KRKQGSVRGL   (SEQ ID NO:24)                       &gt; B034-A04@P11217_15           KQISVRGL   (SEQ ID NO:25)                       &gt; B034-A18@P11217_15           KRKQISGRGL   (SEQ ID NO:26)                       &gt; B034-A07@P11217_15           RKQISVR   (SEQ ID NO:27)                       &gt; B034-A19@P11217_15           RKEISVR   (SEQ ID NO:28)                       &gt; B034-A21@P11217_15           RKQITVR   (SEQ ID NO:29)                       &gt; B034-A10@P11217_15           KAKQISVRGL   (SEQ ID NO:30)                       &gt; B034-A11@P11217_15           KKQISVR   (SEQ ID NO:31)                       &gt; B034-A12@P11217_15           KRAQISVRGL   (SEQ ID NO:32)                       &gt; B034-A14@P11217_15           KRKQISVAGL   (SEQ ID NO:33)                       &gt; B034-A15@P11217_15           KRKQISVGGL   (SEQ ID NO:34)                            EGFR (autophosphorylation)               1.3.5.                &gt; B046-I@P06268_1172                   DNPDYQQDF   (SEQ ID NO:35)                       &gt; B046-J@P06268_1197           ENAEYLRVA   (SEQ ID NO:36)                       &gt; B046-F@P06268_1016           DADEYLIPQ   (SEQ ID NO:37)                       &gt; B046-G@P06268_1092           PVPEYINQS   (SEQ ID NO:38)                       &gt; B046-H@P06268_1110           QNPVYHNQP   (SEQ ID NO:39)                       phospho           1.1.0.           &gt; B060-A@P14598_303           PPRRSSIRN   (SEQ ID NO:40)                       &gt; B060-B@P14598_304           PRRSSIRNA   (SEQ ID NO:41)                       &gt; B060-C@P14598_315           IHQRSRKRL   (SEQ ID NO:42)                       &gt; B060-E@P14598_328           YRRNSVRFL   (SEQ ID NO:43)                       &gt; B060-F@P14598_345           PGPQSPGSP   (SEQ ID NO:44)                       &gt; B060-G@P14598_348           QSPGSPLEE   (SEQ ID NO:45)                       &gt; B060-H@P14598_379           LNRCSESTK   (SEQ ID NO:46)          
 
         [0182]    The following output represents an example with more proven phosphorylation sites segmented by both categories: class (acceptor residues) and subclass (kinase). Kinases belonging to the subclasses PKC, PKA and p34cdc2 and also unknown kinases phospho are used in the matrix construction.  
                                                 =============================================================================           seq(    0..  59) GSSKSKPKDPSQRRRSLEPPDSTHHGGFPASQTPNKTAAPDTHRTPSRSFGTVATEPKLF       -----------------------------------------------------------------------------            Phase 3                       1.1.0   42   50   nnnPSnnnn   (SEQ. ID NO:47)               1.1.0   +A001-C   HRTPSRSFG   (SEQ. ID NO:48)               1.1.0   +B046-A   PLTPSGEAP   (SEQ. ID NO:49)               1.1.0   +B094-G   ERSPSPSFR   (SEQ. ID NO:50)               1.1.0   +B146-A   LLRPSRRVR   (SEQ. ID NO:51)               ; Sim = 50.0003;   Conservation = 78               |||||||||                       |||||||||                       |||||||||                       |||||||||                        ||||||||               XX       1.1.1   6    14   nnnnSnRRn               1.1.1   + A001-A   PKDPSQRRR   (SEQ ID NO:52)               1.1.1   + B007-A   QKRPSQRSK   (SEQ ID NO:53)               1.1.1   + B030-B   PRRVSRRRR   (SEQ ID NO:54)               1.1.1   + B116-B   TQSTSGRRR   (SEQ ID NO:55)               1.1.1   + B117-C   PRRVSRRRR   (SEQ ID NO:56)               1.1.1   + B176-A   METPSQRRA   (SEQ ID NO:57)               1.1.1   + B177-A   METPSQRRA   (SEQ ID NO:58)               ; Sim = 33.3336;   Conservation = 78               |||||||||                       |||||||||                       |||||||||                       |||||||||                       |||||||||               XX       1.1.2   11   19   nRRnSnnnn               1.1.2   + A001-B   QRRRSLEPP   (SEQ ID NO:59)               1.1.2   + B021-A   RRRGSSIPQ   (SEQ ID NO:60)               1.1.2   + B028-A   AVRRSDRAY   (SEQ ID NO:61)               1.1.2   + B049-B   GRRQSLIQD   (SEQ ID NO:62)               1.1.2   + B064-B   SRKRSGEAT   (SEQ ID NO:63)               1.1.2   + B066-B   TTRRSCSKT   (SEQ ID NO:64)               1.1.2   + B067-B   KSRPSLPLP   (SEQ ID NO:65)               1.1.2   + B091-B   LCRRSTTDC   (SEQ ID NO:66)               1.1.2   + B092-A   LRRFSLATM   (SEQ ID NO:67)               1.1.2   + B093-A   LRRFSLATM   (SEQ ID NO:68)               1.1.2   + B100-A   PRRDSTEGF   (SEQ ID NO:69)               1.1.2   + B101-A   MRRNSFTPL   (SEQ ID NO:70)               1.1.2   + B103-A   AARLSLTDP   (SEQ ID NO:71)               1.1.2   + B110-A   PRRRSSFGI   (SEQ ID NO:72)               1.1.2   + B114-D   ERRKSHEAE   (SEQ ID NO:73)               1.1.2   + B115-B   SRRDSLFVP   (SEQ ID NO:74)               1.1.2   + B135-B   ERTNSLPPV   (SEQ ID NO:75)               1.1.2   + B135-C   QRRTSLTGS   (SEQ ID NO:76)               1.1.2   + B135-E   SRRSSLGSL   (SEQ ID NO:77)               1.1.2   + B145-C   PRMPSLSVP   (SEQ ID NO:78)               1.1.2   + B233-A   QRRHSLEPP   (SEQ ID NO:79)               ; Sim = 100;   Conservation = 75   |||||||||                       |||||||||                       |||||||||                       |||||||||                        || |               XX       1.2.3   28  36   nnnnTPNKn               1.2.3   + A001-E   PASQTPNKT   (SEQ ID NO:80)               1.2.3   + B267-D   GGTGTPNKE   (SEQ ID NO:81)               1.2.3   + B268-F   SASGTPNKE   (SEQ ID NO:82)               ; Sim = 25.0003;   Conservation = 86   |||||||||                       |||||||||                       |||||||||                       |||||||||                       |||||||||               XX       Segments:       1.1.1    6 14   = = = = PKC = =               1.1.2   11 19            = = = = PKA = =               1.2.3   28 36                                = = p34cdc2               1.1.0   42 50                                            = = phospho          
 
         [0183]    The features of the present invention disclosed in the specification, the claims and/or the drawings may both separately and in any combination thereof be material for realizing the invention in various forms thereof.  
     
       
       
         1 
         
           
             82  
           
           
             1  
             11  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            1 

Leu Lys Leu Ala Ser Pro Glu Leu Glu Leu Lys 
 1               5                  10 

 
           
             2  
             11  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            2 

Glu Lys Leu Ala Ser Lys Glu Leu Glu Val Asp 
 1               5                  10 

 
           
             3  
             50  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            3 

Leu Val Val Leu Thr Ile Ile Ser Leu Ile Ile Leu Ile Met Leu Trp 
 1               5                  10                  15 

Gln Lys Lys Pro Arg Tyr Glu Ile Arg Trp Lys Val Ile Glu Ser Val 
            20                  25                  30 

Ser Ser Asp Gly His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu Pro 
        35                  40                  45 

Tyr Asp 
    50 

 
           
             4  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            4 

Phe Pro Val Ser Tyr Ser Ser Ser Gly 
 1               5 

 
           
             5  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            5 

Ser Asp Gly Gly Tyr Met Asp Met Ser 
 1               5 

 
           
             6  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            6 

Asp Gly His Glu Tyr Ile Tyr Val Asp 
 1               5 

 
           
             7  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            7 

Lys Gly His Glu Tyr Thr Asn Ile Lys 
 1               5 

 
           
             8  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            8 

Lys Ala Glu Glu Tyr Ile Leu Lys Lys 
 1               5 

 
           
             9  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            9 

His Glu Tyr Ile Tyr Val Asp Pro Met 
 1               5 

 
           
             10  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            10 

Asn Asn Tyr Val Tyr Ile Asp Pro Thr 
 1               5 

 
           
             11  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            11 

Tyr Met Ala Pro Tyr Asp Asn Tyr Tyr 
 1               5 

 
           
             12  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            12 

Met Met Thr Pro Tyr Val Val Thr Arg 
 1               5 

 
           
             13  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            13 

Pro Tyr Asp Asn Tyr Val Pro Ser Ala 
 1               5 

 
           
             14  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            14 

Glu Ser Leu Glu Ser Tyr Glu Ile Asn 
 1               5 

 
           
             15  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            15 

Met Ala Glu Val Ser Trp Lys Val Leu 
 1               5 

 
           
             16  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            16 

Glu Ile Val Glu Ser Leu Ser Ser Ser 
 1               5 

 
           
             17  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            17 

Gly Val Arg Gln Ser Arg Ala Ser Asp 
 1               5 

 
           
             18  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            18 

Val Glu Ser Leu Ser Ser Ser Glu Glu 
 1               5 

 
           
             19  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            19 

Leu Gln Arg Tyr Ser Ser Asp Pro Thr 
 1               5 

 
           
             20  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized phosphorylation site  
             
           
            20 

Asp Asn Asn Glu Tyr Asn Asn Asn Asp 
 1               5 

 
           
             21  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized phosphorylation site  
             
           
            21 

Asn Asn Tyr Asn Tyr Asn Asp Pro Asn 
 1               5 

 
           
             22  
             8  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            22 

Lys Gln Gly Ser Gly Arg Gly Leu 
 1               5 

 
           
             23  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            23 

Lys Arg Lys Gln Ile Ser Val Arg Gly Leu 
 1               5                  10 

 
           
             24  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            24 

Lys Arg Lys Gln Gly Ser Val Arg Gly Leu 
 1               5                  10 

 
           
             25  
             8  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            25 

Lys Gln Ile Ser Val Arg Gly Leu 
 1               5 

 
           
             26  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            26 

Lys Arg Lys Gln Ile Ser Gly Arg Gly Leu 
 1               5                  10 

 
           
             27  
             7  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            27 

Arg Lys Gln Ile Ser Val Arg 
 1               5 

 
           
             28  
             7  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            28 

Arg Lys Glu Ile Ser Val Arg 
 1               5 

 
           
             29  
             7  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            29 

Arg Lys Gln Ile Thr Val Arg 
 1               5 

 
           
             30  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            30 

Lys Ala Lys Gln Ile Ser Val Arg Gly Leu 
 1               5                  10 

 
           
             31  
             7  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            31 

Lys Lys Gln Ile Ser Val Arg 
 1               5 

 
           
             32  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            32 

Lys Arg Ala Gln Ile Ser Val Arg Gly Leu 
 1               5                  10 

 
           
             33  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            33 

Lys Arg Lys Gln Ile Ser Val Ala Gly Leu 
 1               5                  10 

 
           
             34  
             10  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            34 

Lys Arg Lys Gln Ile Ser Val Gly Gly Leu 
 1               5                  10 

 
           
             35  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            35 

Asp Asn Pro Asp Tyr Gln Gln Asp Phe 
 1               5 

 
           
             36  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            36 

Glu Asn Ala Glu Tyr Leu Arg Val Ala 
 1               5 

 
           
             37  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            37 

Asp Ala Asp Glu Tyr Leu Ile Pro Gln 
 1               5 

 
           
             38  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            38 

Pro Val Pro Glu Tyr Ile Asn Gln Ser 
 1               5 

 
           
             39  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            39 

Gln Asn Pro Val Tyr His Asn Gln Pro 
 1               5 

 
           
             40  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            40 

Pro Pro Arg Arg Ser Ser Ile Arg Asn 
 1               5 

 
           
             41  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            41 

Pro Arg Arg Ser Ser Ile Arg Asn Ala 
 1               5 

 
           
             42  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            42 

Ile His Gln Arg Ser Arg Lys Arg Leu 
 1               5 

 
           
             43  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            43 

Tyr Arg Arg Asn Ser Val Arg Phe Leu 
 1               5 

 
           
             44  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized known phosphorylation site  
             
           
            44 

Pro Gly Pro Gln Ser Pro Gly Ser Pro 
 1               5 

 
           
             45  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized modify phosphorylation site  
             
           
            45 

Gln Ser Pro Gly Ser Pro Leu Glu Glu 
 1               5 

 
           
             46  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized modify phosphorylation site  
             
           
            46 

Leu Asn Arg Cys Ser Glu Ser Thr Lys 
 1               5 

 
           
             47  
             60  
             PRT  
             Artificial Sequence  
             
               synthesized examined sequence  
             
           
            47 

Gly Ser Ser Lys Ser Lys Pro Lys Asp Pro Ser Gln Arg Arg Arg Ser 
 1               5                  10                  15 

Leu Glu Pro Pro Asp Ser Thr His His Gly Gly Phe Pro Ala Ser Gln 
            20                  25                  30 

Thr Pro Asn Lys Thr Ala Ala Pro Asp Thr His Arg Thr Pro Ser Arg 
        35                  40                  45 

Ser Phe Gly Thr Val Ala Thr Glu Pro Lys Leu Phe 
    50                  55                  60 

 
           
             48  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            48 

His Arg Thr Pro Ser Arg Ser Phe Gly 
 1               5 

 
           
             49  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            49 

Pro Leu Thr Pro Ser Gly Glu Ala Pro 
 1               5 

 
           
             50  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            50 

Glu Arg Ser Pro Ser Pro Ser Phe Arg 
 1               5 

 
           
             51  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            51 

Leu Leu Arg Pro Ser Arg Arg Val Arg 
 1               5 

 
           
             52  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            52 

Pro Lys Asp Pro Ser Gln Arg Arg Arg 
 1               5 

 
           
             53  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            53 

Gln Lys Arg Pro Ser Gln Arg Ser Lys 
 1               5 

 
           
             54  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            54 

Pro Arg Arg Val Ser Arg Arg Arg Arg 
 1               5 

 
           
             55  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            55 

Thr Gln Ser Thr Ser Gly Arg Arg Arg 
 1               5 

 
           
             56  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            56 

Pro Arg Arg Val Ser Arg Arg Arg Arg 
 1               5 

 
           
             57  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            57 

Met Glu Thr Pro Ser Gln Arg Arg Ala 
 1               5 

 
           
             58  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            58 

Met Glu Thr Pro Ser Gln Arg Arg Ala 
 1               5 

 
           
             59  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            59 

Gln Arg Arg Arg Ser Leu Glu Pro Pro 
 1               5 

 
           
             60  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            60 

Arg Arg Arg Gly Ser Ser Ile Pro Gln 
 1               5 

 
           
             61  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            61 

Ala Val Arg Arg Ser Asp Arg Ala Tyr 
 1               5 

 
           
             62  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            62 

Gly Arg Arg Gln Ser Leu Ile Gln Asp 
 1               5 

 
           
             63  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            63 

Ser Arg Lys Arg Ser Gly Glu Ala Thr 
 1               5 

 
           
             64  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            64 

Thr Thr Arg Arg Ser Cys Ser Lys Thr 
 1               5 

 
           
             65  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            65 

Lys Ser Arg Pro Ser Leu Pro Leu Pro 
 1               5 

 
           
             66  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            66 

Leu Cys Arg Arg Ser Thr Thr Asp Cys 
 1               5 

 
           
             67  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            67 

Leu Arg Arg Phe Ser Leu Ala Thr Met 
 1               5 

 
           
             68  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            68 

Leu Arg Arg Phe Ser Leu Ala Thr Met 
 1               5 

 
           
             69  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            69 

Pro Arg Arg Asp Ser Thr Glu Gly Phe 
 1               5 

 
           
             70  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            70 

Met Arg Arg Asn Ser Phe Thr Pro Leu 
 1               5 

 
           
             71  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            71 

Ala Ala Arg Leu Ser Leu Thr Asp Pro 
 1               5 

 
           
             72  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            72 

Pro Arg Arg Arg Ser Ser Phe Gly Ile 
 1               5 

 
           
             73  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            73 

Glu Arg Arg Lys Ser His Glu Ala Glu 
 1               5 

 
           
             74  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            74 

Ser Arg Arg Asp Ser Leu Phe Val Pro 
 1               5 

 
           
             75  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            75 

Glu Arg Thr Asn Ser Leu Pro Pro Val 
 1               5 

 
           
             76  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            76 

Gln Arg Arg Thr Ser Leu Thr Gly Ser 
 1               5 

 
           
             77  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            77 

Ser Arg Arg Ser Ser Leu Gly Ser Leu 
 1               5 

 
           
             78  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            78 

Pro Arg Met Pro Ser Leu Ser Val Pro 
 1               5 

 
           
             79  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            79 

Gln Arg Arg His Ser Leu Glu Pro Pro 
 1               5 

 
           
             80  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            80 

Pro Ala Ser Gln Thr Pro Asn Lys Thr 
 1               5 

 
           
             81  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            81 

Gly Gly Thr Gly Thr Pro Asn Lys Glu 
 1               5 

 
           
             82  
             9  
             PRT  
             Artificial Sequence  
             
               synthesized proven phosphorylation site  
             
           
            82 

Ser Ala Ser Gly Thr Pro Asn Lys Glu 
 1               5